Chemicals · Founded 1975 · www.gelatin.in · BSE 506532 · NSE NITTA GELA · ISIN INE265B01019
No Notes Added Yet
Business
Nitta Gelatin India Ltd. (NGIL) is a leading manufacturer and supplier of gelatin and collagen peptides. The company's core business involves processing animal by-products, primarily ossein (a collagen derivative from bovine bones) and hide, into high-quality gelatin. This gelatin serves critical functions in various industries, including pharmaceuticals (e.g., hard and soft-gel capsules), food (e.g., confectionery, dairy products, desserts), and photographic film. More recently, the company has expanded its focus on collagen peptides for the nutraceutical and health supplement markets. NGIL makes money by selling these specialized protein products to business customers across these sectors.
Revenue Mix
The primary revenue segments for Nitta Gelatin India Ltd. are:
Gelatin: This is the largest segment, catering mainly to the pharmaceutical industry for capsule manufacturing, followed by the food industry for various applications, and a smaller portion for photographic film.
Collagen Peptides: This is a growing segment, driven by demand from the nutraceutical and health supplement industries for products promoting skin health, joint health, and overall well-being.
While specific revenue percentages are not publicly detailed in brief overviews, gelatin for pharmaceuticals is historically a significant contributor.
Industry
The gelatin and collagen peptides industry is a specialized segment within the broader chemicals sector, characterized by stringent quality requirements, regulatory compliance, and reliance on animal by-products. Globally, it's a moderately concentrated market with a few large multinational players and regional specialists.
Nitta Gelatin India Ltd. is a prominent player in the Indian market for gelatin. It benefits significantly from being a joint venture with Nitta Gelatin Inc. of Japan, a global leader in the field. This association provides NGIL access to advanced technology, R&D capabilities, and global market insights, positioning it as a technologically capable and quality-focused manufacturer against domestic and international competitors.
MOAT
Technological Expertise & R&D: Leveraging its parent company, Nitta Gelatin Inc. (Japan), NGIL has access to advanced manufacturing processes, R&D capabilities, and quality control systems essential for high-grade gelatin and collagen peptide production.
Quality & Certifications: The company's products meet stringent international quality standards and certifications (e.g., GMP for pharma, Halal, Kosher), which are critical for its key customers in the pharmaceutical and food industries, creating a barrier to entry for new players.
Established Customer Relationships: Long-standing relationships with major pharmaceutical companies and food manufacturers in India and abroad provide stable demand and repeat business.
Raw Material Sourcing Network: An established and reliable supply chain for animal by-products (bones, hides) is crucial for consistent production, representing a significant operational advantage.
Growth Drivers
Pharmaceutical Sector Growth: Continued expansion of the Indian pharmaceutical industry, especially in oral dosage forms, drives demand for gelatin capsules.
Nutraceutical and Health Supplements: Growing health awareness and increasing consumer spending on collagen-based supplements will fuel demand for collagen peptides.
Food & Beverage Industry Expansion: Rising consumption of processed foods, confectioneries, and dairy products in India supports demand for food-grade gelatin.
Export Opportunities: Leveraging its global parent network and competitive manufacturing costs, NGIL can expand its reach into international markets.
Product Diversification: Focus on high-value-added products like specialized collagen peptides for niche applications.
Risks
Raw Material Price Volatility & Availability: Dependence on animal by-products (bovine bones/hide) makes the company susceptible to price fluctuations due to livestock availability, disease outbreaks, and global supply-demand dynamics.
Regulatory Changes: Stringent and evolving regulations in the pharmaceutical, food, and environmental sectors can impact production processes, product specifications, and operational costs.
Competition: Intense competition from domestic and international gelatin manufacturers, as well as potential synthetic alternatives for some applications, could impact pricing power and market share.
Foreign Exchange Fluctuations: Given its involvement in exports and potentially importing certain equipment or specialized ingredients, currency volatility can affect profitability.
Ethical/Religious Concerns: As an animal-derived product, gelatin can face scrutiny or require specific certifications (Halal, Kosher) to cater to diverse consumer bases, adding complexity to market access.
Management & Ownership
Nitta Gelatin India Ltd. is promoted by Nitta Gelatin Inc. of Japan, which holds a significant controlling stake, making it a key part of a global gelatin manufacturing group. The management team benefits from the technical and operational expertise shared by the Japanese parent company, suggesting a professional and quality-focused approach. The ownership structure is a joint venture, with Nitta Gelatin Inc. as the primary promoter and the remainder held by public shareholders.
Outlook
Nitta Gelatin India Ltd. is strategically positioned in an essential and growing segment of the specialty chemicals market, particularly benefiting from the robust growth of the pharmaceutical and emerging nutraceutical sectors in India. The company's strong technological backing from its Japanese parent, along with a focus on quality and certifications, provides a durable competitive edge.
However, the business faces inherent risks tied to the volatility of raw material prices (animal by-products) and the need for continuous adherence to stringent regulatory standards in its end-user industries. The ability to manage these input costs effectively, innovate within its product portfolio (especially collagen peptides), and expand into export markets will be crucial for sustained growth. While the long-term demand drivers appear favorable, profitability can be sensitive to raw material supply shocks and competitive pressures.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 130 | 130 | 132 | 135 | 129 | 139 | 138 | 150 | 162 | 141 |
| Other Income | 5 | 2 | 4 | 3 | 2 | 2 | 4 | 1 | 5 | 4 |
| Total Income | 136 | 133 | 137 | 137 | 132 | 141 | 142 | 151 | 167 | 145 |
| Total Expenditure | 110 | 102 | 107 | 107 | 106 | 111 | 112 | 112 | 116 | 106 |
| Operating Profit | 25 | 31 | 30 | 30 | 26 | 30 | 30 | 39 | 50 | 38 |
| Interest | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 7 | 4 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 20 | 27 | 27 | 33 | 26 | 26 | 26 | 35 | 46 | 34 |
| Provision for Tax | 6 | 7 | 6 | 8 | 6 | 7 | 7 | 10 | 12 | 9 |
| Profit After Tax | 13 | 20 | 20 | 25 | 20 | 20 | 19 | 26 | 34 | 25 |
| Adjustments | 1 | -1 | 0 | -0 | 0 | -0 | -0 | -0 | -0 | -0 |
| Profit After Adjustments | 14 | 20 | 20 | 24 | 20 | 19 | 18 | 26 | 34 | 25 |
| Adjusted Earnings Per Share | 15.4 | 21.7 | 22.3 | 26.9 | 21.6 | 21.1 | 20.3 | 28.2 | 37.5 | 27.7 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 359 | 356 | 342 | 303 | 342 | 396 | 506 | 565 | 533 | 527 | 588 | 591 |
| Other Income | 2 | 9 | 5 | 1 | 2 | 1 | 5 | 1 | 11 | 10 | 13 | 14 |
| Total Income | 361 | 365 | 347 | 304 | 344 | 398 | 511 | 566 | 544 | 537 | 601 | 605 |
| Total Expenditure | 322 | 320 | 313 | 273 | 306 | 351 | 442 | 452 | 409 | 421 | 451 | 446 |
| Operating Profit | 38 | 45 | 34 | 31 | 37 | 46 | 69 | 114 | 134 | 116 | 150 | 157 |
| Interest | 8 | 7 | 7 | 9 | 8 | 6 | 5 | 4 | 3 | 2 | 1 | 0 |
| Depreciation | 13 | 14 | 15 | 15 | 16 | 16 | 14 | 14 | 15 | 13 | 15 | 16 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 12 | 0 | 0 |
| Profit Before Tax | 18 | 24 | 12 | 7 | 13 | 25 | 49 | 99 | 116 | 113 | 133 | 141 |
| Provision for Tax | 10 | 12 | 7 | 2 | 1 | 7 | 14 | 25 | 32 | 28 | 35 | 38 |
| Profit After Tax | 9 | 12 | 5 | 5 | 12 | 18 | 35 | 74 | 84 | 85 | 98 | 104 |
| Adjustments | 2 | 2 | -0 | -1 | -1 | -1 | -2 | -4 | -1 | -1 | -1 | 0 |
| Profit After Adjustments | 11 | 14 | 4 | 3 | 11 | 17 | 33 | 70 | 83 | 84 | 97 | 103 |
| Adjusted Earnings Per Share | 11 | 15.6 | 4.9 | 3.8 | 12.4 | 19.1 | 36.3 | 77.4 | 91 | 92.5 | 107.1 | 113.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 12% | 1% | 8% | 5% |
| Operating Profit CAGR | 29% | 10% | 27% | 15% |
| PAT CAGR | 15% | 10% | 40% | 27% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 80% | 25% | 45% | 22% |
| ROE Average | 21% | 24% | 24% | 15% |
| ROCE Average | 28% | 31% | 29% | 19% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 130 | 134 | 149 | 151 | 153 | 173 | 201 | 268 | 343 | 422 | 511 |
| Minority's Interest | 4 | 3 | 1 | 3 | 3 | 3 | 4 | 7 | 7 | 7 | 4 |
| Borrowings | 34 | 40 | 38 | 34 | 29 | 23 | 7 | 7 | 4 | 4 | 0 |
| Other Non-Current Liabilities | 10 | 15 | 5 | 4 | -0 | 5 | 9 | 3 | 5 | 7 | 7 |
| Total Current Liabilities | 78 | 110 | 114 | 122 | 107 | 103 | 125 | 83 | 63 | 75 | 63 |
| Total Liabilities | 256 | 301 | 306 | 313 | 292 | 306 | 345 | 367 | 423 | 515 | 586 |
| Fixed Assets | 120 | 110 | 113 | 130 | 121 | 113 | 107 | 114 | 114 | 117 | 148 |
| Other Non-Current Assets | 14 | 35 | 43 | 34 | 36 | 29 | 34 | 32 | 38 | 57 | 44 |
| Total Current Assets | 122 | 156 | 150 | 149 | 135 | 165 | 204 | 221 | 270 | 341 | 389 |
| Total Assets | 256 | 301 | 306 | 313 | 292 | 306 | 345 | 367 | 423 | 515 | 586 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 2 | 1 | 4 | 3 | 5 | 1 | 1 | 2 | 30 | 34 | 112 |
| Cash Flow from Operating Activities | 20 | 11 | 27 | 22 | 40 | 19 | 17 | 101 | 94 | 75 | 122 |
| Cash Flow from Investing Activities | -14 | -3 | -7 | -14 | -10 | -7 | -14 | -18 | -54 | -9 | -182 |
| Cash Flow from Financing Activities | 18 | -5 | -20 | -7 | -33 | -12 | -2 | -55 | -36 | 11 | -37 |
| Net Cash Inflow / Outflow | 25 | 3 | -0 | 1 | -3 | -0 | 1 | 28 | 4 | 77 | -97 |
| Closing Cash & Cash Equivalent | 27 | 4 | 3 | 5 | 1 | 1 | 2 | 30 | 34 | 112 | 14 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 10.95 | 15.6 | 4.91 | 3.82 | 12.38 | 19.15 | 36.26 | 77.44 | 91.02 | 92.46 | 107.11 |
| CEPS(Rs) | 23.49 | 28.58 | 21.62 | 21.95 | 30.82 | 36.85 | 54.21 | 96.95 | 109.32 | 107.95 | 124.69 |
| DPS(Rs) | 2.5 | 2.5 | 2.5 | 1.5 | 2.5 | 3 | 4 | 7.5 | 6 | 8 | 7 |
| Book NAV/Share(Rs) | 126.01 | 147.09 | 163.61 | 165.83 | 168.9 | 190.58 | 221.25 | 294.75 | 378.26 | 464.7 | 563.1 |
| Core EBITDA Margin(%) | 9.75 | 10.02 | 8.46 | 9.96 | 10.43 | 11.33 | 12.68 | 20.04 | 23.09 | 19.98 | 23.23 |
| EBIT Margin(%) | 6.93 | 8.71 | 5.42 | 5.31 | 6.35 | 7.78 | 10.75 | 18.22 | 22.35 | 21.64 | 22.84 |
| Pre Tax Margin(%) | 4.89 | 6.74 | 3.46 | 2.41 | 3.9 | 6.37 | 9.69 | 17.48 | 21.79 | 21.33 | 22.59 |
| PAT Margin (%) | 2.31 | 3.44 | 1.34 | 1.62 | 3.6 | 4.51 | 6.87 | 13.04 | 15.75 | 16.05 | 16.66 |
| Cash Profit Margin (%) | 5.75 | 7.3 | 5.72 | 6.56 | 8.15 | 8.42 | 9.71 | 15.53 | 18.59 | 18.56 | 19.19 |
| ROA(%) | 3.57 | 4.39 | 1.52 | 1.59 | 4.08 | 5.99 | 10.69 | 20.75 | 21.3 | 18.08 | 17.85 |
| ROE(%) | 7.69 | 9.87 | 3.26 | 3.29 | 8.13 | 10.99 | 18.64 | 31.55 | 27.53 | 22.15 | 21.06 |
| ROCE(%) | 13.52 | 13.8 | 7.52 | 6.32 | 8.8 | 12.61 | 20.19 | 34.77 | 35.93 | 28.22 | 27.83 |
| Receivable days | 20.95 | 37.36 | 60.6 | 75.09 | 51.93 | 44.48 | 54.47 | 56.87 | 59.14 | 62.21 | 59.51 |
| Inventory Days | 57.33 | 69.42 | 78.01 | 85.78 | 85.65 | 84.61 | 70.37 | 63.02 | 64.75 | 65.05 | 54.89 |
| Payable days | 46.66 | 46.04 | 52.11 | 64.1 | 48.7 | 40.09 | 30.09 | 33.55 | 45.11 | 40.6 | 45.26 |
| PER(x) | 18.65 | 12.23 | 40.59 | 32.97 | 7.21 | 8.71 | 7.8 | 11.48 | 9.17 | 7.09 | 7.37 |
| Price/Book(x) | 1.62 | 1.3 | 1.22 | 0.76 | 0.53 | 0.88 | 1.28 | 3.02 | 2.21 | 1.41 | 1.4 |
| Dividend Yield(%) | 1.22 | 1.31 | 1.26 | 1.19 | 2.8 | 1.8 | 1.41 | 0.84 | 0.72 | 1.22 | 0.89 |
| EV/Net Sales(x) | 0.7 | 0.75 | 0.81 | 0.71 | 0.48 | 0.58 | 0.67 | 1.44 | 1.31 | 0.92 | 0.92 |
| EV/Core EBITDA(x) | 6.51 | 5.97 | 8.24 | 6.95 | 4.34 | 4.93 | 4.93 | 7.13 | 5.17 | 4.22 | 3.62 |
| Net Sales Growth(%) | 0.32 | -0.79 | -3.82 | -11.43 | 12.91 | 15.81 | 27.69 | 11.74 | -5.77 | -1.16 | 11.72 |
| EBIT Growth(%) | 129.86 | 20.43 | -39.97 | -13.21 | 35.19 | 41.66 | 76.42 | 89.34 | 15.6 | -4.24 | 17.86 |
| PAT Growth(%) | 338.78 | 42.91 | -62.4 | 7 | 150.9 | 45.17 | 94.37 | 112.07 | 13.81 | 0.79 | 15.89 |
| EPS Growth(%) | 801.36 | 42.48 | -68.55 | -22.08 | 223.86 | 54.65 | 89.36 | 113.58 | 17.54 | 1.57 | 15.85 |
| Debt/Equity(x) | 0.59 | 0.81 | 0.7 | 0.72 | 0.55 | 0.46 | 0.43 | 0.15 | 0.04 | 0.07 | 0.01 |
| Current Ratio(x) | 1.56 | 1.41 | 1.32 | 1.22 | 1.26 | 1.6 | 1.64 | 2.68 | 4.27 | 4.58 | 6.15 |
| Quick Ratio(x) | 0.78 | 0.74 | 0.68 | 0.65 | 0.41 | 0.7 | 0.82 | 1.55 | 2.75 | 3.35 | 4.8 |
| Interest Cover(x) | 3.4 | 4.43 | 2.77 | 1.83 | 2.6 | 5.53 | 10.17 | 24.8 | 40.32 | 69.51 | 93.24 |
| Total Debt/Mcap(x) | 0.41 | 0.63 | 0.57 | 0.94 | 1.03 | 0.53 | 0.34 | 0.05 | 0.02 | 0.05 | 0.01 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.48 | 74.48 | 74.48 | 74.48 | 74.48 | 74.48 | 74.48 | 74.48 | 74.48 | 74.48 |
| FII | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.05 | 0.06 |
| DII | 0.11 | 0.11 | 0.08 | 0.09 | 0.35 | 0.64 | 0.74 | 0.92 | 0.95 | 0.98 |
| Public | 25.39 | 25.4 | 25.44 | 25.43 | 25.16 | 24.88 | 24.77 | 24.59 | 24.52 | 24.47 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Public | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.22 | 0.22 | 0.22 | 0.22 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +12% | +1% | +8% | +5% |
| Operating Profit CAGR | +29% | +10% | +27% | +15% |
| PAT CAGR | +15% | +10% | +40% | +27% |
| Share Price CAGR | +80% | +25% | +45% | +22% |
| ROE Average | +21% | +24% | +24% | +15% |
| ROCE Average | +28% | +31% | +29% | +19% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.48 | 74.48 | 74.48 | 74.48 | 74.48 | 74.48 | 74.48 | 74.48 | 74.48 | 74.48 |
| FII | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.05 | 0.06 |
| DII | 0.11 | 0.11 | 0.08 | 0.09 | 0.35 | 0.64 | 0.74 | 0.92 | 0.95 | 0.98 |
| Public | 25.39 | 25.4 | 25.44 | 25.43 | 25.16 | 24.88 | 24.77 | 24.59 | 24.52 | 24.47 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Public | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.22 | 0.22 | 0.22 | 0.22 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.